secwatch.observer — SEC 8-K summary
======================================

Issuer:     NeuroPace Inc (NPCE)
CIK:        0001528287
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001528287-25-000006
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroPace reports Q4 revenue $21.5M (+19% YoY); guides FY2025 revenue $92-96M
-----------------------------------------------------------------------------

- Q4 2024 revenue $21.5M (+19% YoY); full year revenue $79.9M (+22%).
- Net loss improved: Q4 $5.3M (vs $6.2M); full year $27.1M (vs $33.0M).
- FY2025 guidance: revenue $92-96M (15-20% growth), gross margin 73-75%, operating expenses $92-95M.
- Completed $74.8M public offering; used $49.5M to repurchase 5.3M shares from KCK Ltd.; pro forma cash $68.6M.
- NAUTILUS study completes March 2025; FDA submission H2 2025; NEST pediatric program for indication expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528287/000152828725000006/0001528287-25-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528287/000152828725000006/npce-20250304.htm
  HTML page:      https://secwatch.observer/filing/0001528287-25-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer